Clinical Trial Update: Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) [Phase 2]

View source ↗

Summary

This document reports the completion and posting of results from a Phase 2 trial evaluating the efficacy, safety, and tolerability of Rasagiline Mesylate 1 mg i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• Rasagiline mesylate (RASAGILINE MESYLATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Multiple System Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2015-02-26